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ABSTRACT
Background: Type-2 diabetes mellitus (T2DM) is a risk
factor for progressive non-alcoholic fatty liver disease
(NAFLD). Drugs commonly prescribed in patients with
T2DM may affect liver histology by interfering with lipid
metabolism and insulin resistance/secretion.
Aim: We studied if statins or antidiabetic agents were
associated with non-alcoholic steatohepatitis (NASH)
and significant fibrosis (SF).
Methods: We performed a cross-sectional study of
346 diabetics with biopsy-proven NAFLD. T2DM was
defined as fasting glucose ≥7 mmol/L or glycated
haemoglobin ≥6.5% and/or use of antidiabetics. NASH
was defined according to the FLIP algorithm and SF as
F2–4 Kleiner’s stages.
Results: 84% of patients were on antidiabetic therapy
and 45% on statins. NASH and SF were present in 57%
and 48% of patients. Statin-treated patients were older,
more frequently male and with poorer glycaemic
control despite more frequent antidiabetic therapy than
those without statins; however, the prevalence of NASH
(57%vs56%, p=0.868) and SF (48%vs48%, p=0.943)
was not different between statin users and non-users.
NASH was more common in patients on metformin or
insulin than in those not treated with these drugs (60%
vs47%, p=0.026; 68%vs53%, p=0.017). SF was more
common in those treated with sulfonylureas (57%
vs44%, p=0.030). Multivariate analyses confirmed that
use of statins was independently and negatively
associated with both NASH (OR (95% CI) 0.57 (0.32 to
1.01), p=0.055) and SF (OR (95% CI) 0.47 (0.26 to
0.84), p=0.011). Moreover, we found independent
associations between insulin use and NASH (OR (95%
CI) 2.24 (1.11 to 4.54), p=0.025) and sulfonylureas use
and SF (OR (95% CI) 2.04 (1.11 to 3.74), p=0.022).
Conclusions: Several medications used in patients
with diabetes are differently associated with NAFLD
histology. Statin use is negatively associated, while
insulin and sulfonylureas are positively associated with
NASH and SF. A wider use of statins may be warranted
in this high-risk population.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD)
covers a spectrum of liver injury strongly
associated with type-2 diabetes mellitus
(T2DM) as the prevalence of NAFLD in
diabetics ranges from 40% to 70%.1 2
Importantly, NAFLD is also associated with
cardiovascular disease, and this association is
believed to be independent of traditional
cardiovascular risk factors.3 NAFLD patients
with T2DM are thus at high risk for progres-
sive liver and cardiovascular disease. In this
population, statins should be largely pre-
scribed to achieve low-density lipoprotein
Summary box
What is already known about this subject?
▸ Type 2 diabetes mellitus is a risk factor for pro-
gressive non-alcoholic fatty liver disease
(NAFLD).
▸ Drugs commonly prescribed in patients with
type 2 diabetes mellitus may affect liver hist-
ology by interfering with insulin sensitivity and
lipid profile.
▸ Despite their good safety profile in patients with
chronic liver diseases, and current recommenda-
tions for a wider use in patients with diabetes,
statins remain underprescribed.
What are the new findings?
▸ In patients with diabetes with NAFLD, statins
show a significant and independent negative
association with NASH and significant fibrosis.
▸ Conversely, insulin and sulfonylureas are inde-
pendently and positively associated with the
presence of NASH and significant fibrosis,
respectively.
▸ Therapies commonly used for cardiovascular
prevention or glycaemic control are differently
associated with necroinflammation and fibrosis
in NAFLD diabetic patients.
How might it impact on clinical practice in
the foreseeable future?
▸ The potential protective effect of statins may
warrant their wider use in high-risk, diabetic,
NAFLD patients.
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cholesterol targets, and antidiabetic agents are required
for optimal glycaemic control.4 We postulated that these
common medications may also affect liver histology and
therefore performed a retrospective analysis aimed to
establish the association between the use of these drugs
and the severity of liver injury in NAFLD.
Statins are generally safe in patients with liver disease
and there is no evidence for drug-induced liver injury in
patients with chronic liver disease, including NAFLD.5–9
Some data even suggest a potentially beneficial effect of
statins on NAFLD histology.10 11 Metformin, the pre-
ferred first-line therapy for TD2M,4 does not appear to
improve liver histology in NAFLD,12–14 although some
evidence suggests a beneficial effect on hepatocellular
carcinoma (HCC) development.15–18 Sulfonylureas and
exogenous insulin are used as a second-line therapy in
patients with more advanced T2DM, or as an alternative
to metformin when poorly tolerated. In contrast to met-
formin, sulfonylureas and insulin have been associated
with an increased risk of HCC,16 18 and their effect on
liver histology in NAFLD has been insufficiently investi-
gated so far.19
In this cross-sectional study, we investigated whether
statin and antidiabetic therapies are associated with stea-
tohepatitis and significant fibrosis in 346 patients with
T2DM and biopsy-proven NAFLD.
METHODS
This cross-sectional study included 346 consecutive
patients with T2DM with biopsy-proven NAFLD,
recruited in two centres, covering the entire spectrum of
T2DM and NAFLD severity: a liver disease department
and a nutrition and obesity clinic at the Pitié-Salpêtrière
Hospital, Paris, France.
Among 420 consecutive patients referred to the liver
disease department (Hepato cohort) for suspected
NAFLD, and submitted to a first liver biopsy between
January 2000 and January 2013, we included 138
patients with T2DM and biopsy-proven NAFLD.
Among 625 consecutive morbidly-obese patients who
underwent bariatric surgery at the department of nutri-
tion (Bariatric cohort) between January 2003 and January
2011, we analysed 208 patients with T2DM and biopsy-
proven NAFLD.
Exclusion Criteria were: chronic liver diseases second-
ary to other aetiologies (notably viral, autoimmune and
inherited chronic liver diseases), alcohol consumption
(>30 g/day for men and >20 g/day for women),
drug-induced NASH. All patients were negative for anti-
hepatitis C virus antibodies and hepatitis B surface
antigen.
The following data were recorded at the time of liver
biopsy: age, medical history, body mass index (BMI) and
blood pressure. Self-reported statin and antidiabetic
therapies at the time of liver biopsy were recorded. The
intensity of statin therapy was graded as low-to-moderate
(simvastatin, pravastatin, fluvastatin or lovastatin) or
moderate-to-high (atorvastatin, rosuvastatin or any statin
in combination with ezetimibe). Laboratory tests
included: aspartate aminotransferase (AST), alanine
aminotransferase (ALT), γ glutamyl transpeptidase
(GGT), fasting glucose, glycated haemoglobin (HbA1c)
and lipid profile.
T2DM was defined as fasting glucose ≥7 mmol/L or
HbA1c ≥6.5% and/or the use of any antidiabetic treat-
ment, according to the ADA statement.20 metabolic syn-
drome (MS) was defined according to the IDF criteria.21
All liver biopsies were adequate in terms of length,
absence of fragmentation and quality of staining with
H&E and Picrosirius Hemalun. All slides were read by
expert liver pathologists (FC and PB). NAFLD was
defined as the presence of steatosis in ≥5% of hepato-
cytes. NASH was diagnosed when steatosis, lobular
inflammation and hepatocellular ballooning were
present, according to the FLIP algorithm.22 Fibrosis was
staged according to Kleiner’s criteria and significant
fibrosis was defined as ≥F2.23 All patients provided
informed consent for performing liver biopsy.
Statistical analysis
Results were expressed as median (IQR) for continu-
ous variables and frequencies (percentages) for categor-
ical variables. Medians were compared by the
Mann-Whitney test and nominal variables by Fisher’s
exact test. One-way ANalysis Of VAriance (ANOVA) and
χ2 were used to test for linear trends. Several multivari-
ate binary logistic regression models were carried out to
identify if statin and antidiabetic therapies were inde-
pendently associated with NASH and significant fibrosis.
Variables were chosen on the basis of clinical judgement
and on the results of univariate analyses: cohort origin,
age, sex, BMI, high blood pressure, lipid profile, HbA1c
control and liver enzymes (ALT, AST and GGT) were
used in all the models. Model 1 included a single drug
among statins, metformin, sulfonylureas or insulin;
model 2 included a number of antidiabetic drugs and a
single drug among statins, metformin, sulfonylureas or
insulin; model 3 included statins and antidiabetic (met-
formin, sulfonylureas and insulin) medications at the
same time. Model 3 was also used in additional multi-
variate binary logistic regression analyses to assess the
independent association between the intensity of statin
therapy and liver damage, and in sensitivity analyses. To
exclude selection bias in the decision of treating with
statins based on suspicion of advanced liver disease or
high aminotransferase levels, we carried out two sensitiv-
ity analyses. The first sensitivity analysis was carried in
non-cirrhotic patients, and the second one after exclud-
ing patients with ALT ≥40 U/L and/or AST ≥40 U/L.
ORs and 95% CIs were reported with p values. A two-
sided p value <0.05 was considered significant. Statistical
analyses were performed using the statistical software
package SPSS, V.17.0 for Windows (SPSS Inc, Illinois,
USA).
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RESULTS
Study population
Three hundred forty six patients with T2DM and biopsy-
proven NAFLD, 40% from the Hepato cohort and 60%
from the Bariatric cohort, were analysed (table 1). There
was a predominance of females and median age was 53
(46–60) years. Median BMI was 42 (32–49) kg/m2 and
93% of patients had MS. One hundred fifty four
patients (45%) were statin-treated, 36 on
low-to-moderate intensity (23 on simvastatin, 10 on pra-
vastatin and 3 on fluvastatin) and 116 on
moderate-to-high intensity (82 on atorvastatin, 24 on
rosuvastatin and 10 on statin combined with ezetimibe).
In two patients (excluded from the subanalysis on statin
treatment intensity), the type of statin was not recorded.
Eighty four per cent of patients were on antidiabetic
therapy. Metformin (74%), sulfonylureas (33%) and
insulin (24%) were most commonly used, and were con-
sidered for further analyses. Dipeptidyl peptidase-4 inhi-
bitors (8%), thiazolidinediones (7%), glucagon-like
peptide 1 analogues (5%), acarbose (4%) and glinides
(1%) were used only in a minority of patients and their
association with liver injury could not be specifically
investigated. Thirty two per cent of patients received a
single antidiabetic agent, 35% a combination of two
and 17% a combination of three or more. Median
HbA1c levels were 7.1 (6.5–8.1)%. NASH was diagnosed
in 196 patients (57%), and significant fibrosis in
167 (48%).
Statin users versus non-users
Statin-treated patients were significantly older, more fre-
quently male, hypertensive and with MS. As expected,
total cholesterol was significantly lower in statin-treated
patients than in patients without statins. Of note, patients
on statins had poorer glycaemic control than those
without statins despite more frequent antidiabetic therapy,
probably reflecting more severe T2DM. However, the
prevalence of NASH (57% vs 56%, p=0.868) and signifi-
cant fibrosis (48% vs 48%, p=0.943) was not different
between statin users and non-users (table 2).
Clinical profile according to antidiabetic therapy
We found significantly positive linear trends between the
number of antidiabetic agents and age, prevalence of
arterial hypertension and MS, and HbA1c levels (p for
linear trend, all <0.001), reflecting more advanced
T2DM in patients treated with multiple antidiabetic
drugs. Moreover, patients treated with multiple antidia-
betic agents were more frequently treated with statins
(no antidiabetic drugs 22% vs 1 drug 30% vs 2 drugs
58% vs 3 or more drugs 63%, p<0.001); accordingly,
they showed lower levels of total cholesterol (p<0.001).
Of note, the higher the number of antidiabetic drugs,
Table 1 General features of the study population
Whole study
population (n=346)
Hepato cohort
(n=138)
Bariatric cohort
(n=208)
Demographic data
Age (years) 53 (46–60) 57 (51–63) 50 (43–56)
Male sex (n (%)) 138 (40) 72 (52) 66 (32)
Cohort origin (hepato/bariatric) (n (%)) 138 (40)/208 (60) − −
Metabolic data
BMI (kg/m2) 42 (32–49) 31 (27–34) 47 (42–54)
High blood pressure (n (%)) 261 (76) 109 (79) 152 (73)
On statins (n (%)) 154 (45) 60 (44) 94 (45)
On antidiabetic drugs (n (%)) 292 (84) 121 (88) 171 (82)
Number of antidiabetic drugs 2 (1–2) 2 (1–2) 2 (1–2)
Metformin (n (%)) 256 (74) 101 (73) 155 (75)
Sulfonylureas (n (%)) 113 (33) 54 (39) 59 (28)
Insulin (n (%)) 84 (24) 31 (23) 53 (26)
Metabolic syndrome (IDF) (n (%)) 312 (93) 117 (89) 195 (96)
Biochemical data
HbA1c (%) 7.1 (6.5–8.1) 7.1 (6.5–7.9) 7.1 (6.6–8.2)
Triglyceridaemia (mmol/L) 1.7 (1.2–2.5) 1.7 (1.2–2.7) 1.7 (1.1–2.4)
Total cholesterol (mmol/L) 4.7 (4.1–5.4) 4.8 (4.0–5.5) 4.6 (4.1–5.4)
HDL cholesterol (mmol/L) 1.1 (0.9–1.3) 1.1 (0.9–1.3) 1.1 (1.0–1.4)
AST (U/L) 31 (24–46) 40 (29–58) 27 (22–38)
ALT (U/L) 41 (27–62) 55 (38–80) 33 (23–49)
GGT (U/L) 51 (32–90) 65 (44–120) 44 (29–70)
Histological data
NASH (n (%)) 196 (57) 84 (61) 112 (54)
Significant fibrosis (F≥2) (n (%)) 167 (48) 79 (57) 88 (42)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, γ glutamyl transpeptidase; HbA1c, glycated
haemoglobin; HDL, high-density lipoprotein cholesterol; IDF, International Diabetes Federation.
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the higher the prevalence of NASH (no drugs 43% vs 1
drug 53% vs 2 drugs 63% vs 3 or more drugs 65%, p for
linear trend=0.005) and significant fibrosis (no drugs
37% vs 1 drug 39% vs 2 drugs 55% vs 3 or more drugs
62%, p for linear trend=0.001).
Patients on metformin were significantly older, had sig-
nificantly higher HbA1c levels and arterial hypertension
and MS more frequently, and were more frequently
treated with statins than patients not on metformin.
NASH was significantly more prevalent in patients treated
with metformin than in those not on this treatment (60%
vs 47%, p=0.026), whereas the prevalence of significant
fibrosis did not significantly differ according to metfor-
min treatment (51% vs 41%, p=0.114) (table 3).
Similarly, patients treated with sulfonylureas were sig-
nificantly older, had significantly higher HbA1c levels
and arterial hypertension and MS more frequently as
well as being on concurrent treatment with statins than
patients without sulfonylureas. There were no significant
differences in NASH prevalence according to treatment
with sulfonylureas (57% vs 57%, p=0.998); however, sig-
nificant fibrosis was more common in patients with sulfo-
nylureas than in patients not taking these drugs (57% vs
44%, p=0.030) (table 3).
Insulin-treated patients had still higher HbA1c levels,
presented more frequently with arterial hypertension
and MS and were more frequently treated with statins
than patients not on insulin. NASH was significantly
more common in patients with than in those without
insulin (68% vs 53%, p=0.017), whereas the prevalence of
significant fibrosis did not differ significantly according
to insulin treatment (56% vs 46%, p=0.105) (table 3).
Independent predictors of NASH
By multivariate binary logistic regression analyses, treat-
ment with statins was negatively associated with NASH
irrespective of the model used (adjusted OR (95% CI)
model 1 0.61 (0.35 to 1.07), p=0.086; model 2 0.57 (0.32
to 1.01), p=0.055; model 3 0.57 (0.32 to 1.01), p=0.055),
although the association did not reach statistical signifi-
cance (table 4 and figure 1A).
Metformin and sulfonylureas use was not significantly
associated with NASH in any models. However, insulin
use showed a positive independent significant associ-
ation with NASH (adjusted OR (95% CI) model 1, 2.15
(1.08 to 4.28), p=0.029; model 2, 2.03 (0.98 to 4.17),
p=0.055; model 3, 2.24 (1.11 to 4.54), p=0.025) (table 4
and figure 1A).
Independent predictors of significant fibrosis
At multivariate binary logistic regression analyses, treat-
ment with statins was significantly and negatively asso-
ciated with significant fibrosis irrespective of the model
used (adjusted OR (95% CI) model 1 0.52 (0.29 to 0.93),
p=0.026; model 2 0.46 (0.26 to 0.83), p=0.010; model 3
0.47 (0.26 to 0.84), p=0.011) (table 4, figure 2A).
Metformin and insulin use was not associated with sig-
nificant fibrosis in any models. However, sulfonylureas
Table 2 Comparisons according to statin use
No statins (n=192) On statins (n=154) p Value
Demographic data
Age (years) 52 (42–58) 55 (48–61) <0.001
Male sex (n (%)) 65 (34) 73 (47) 0.011
Bariatric cohort (n (%)) 114 (59) 94 (61) 0.753
Metabolic data
BMI (kg/m2) 42 (32–50) 42 (33–49) 0.873
High blood pressure (n (%)) 123 (64) 138 (90) <0.001
On antidiabetic drugs (n (%)) 150 (78) 142 (92) <0.001
Number of antidiabetic drugs 1 (1–2) 2 (1–2.25) <0.001
Metformin (n (%)) 125 (65) 131 (85) <0.001
Sulfonylureas (n (%)) 48 (25) 65 (42) 0.001
Insulin (n (%)) 33 (17) 51 (33) 0.001
Metabolic syndrome (n (%)) 160 (88) 152 (100) <0.001
Biochemical data
HbA1c (%) 7.0 (6.3–7.7) 7.5 (6.7–8.5) <0.001
Triglyceridaemia (mmol/L) 1.7 (1.2–2.7) 1.7 (1.1–2.4) 0.567
Total cholesterol (mmol/L) 5.0 (4.3–5.7) 4.3 (3.8–5.1) <0.001
HDL cholesterol (mmol/L) 1.1 (0.9–1.4) 1.1 (1.0–1.3) 0.518
AST (U/L) 32 (25–46) 31 (23–43) 0.178
ALT (U/L) 42 (29–64) 39 (25–61) 0.218
GGT (U/L) 50 (31–86) 54 (33–92) 0.286
Histological data
NASH (n (%)) 108 (56) 88 (57) 0.868
Significant fibrosis (F≥2) (n (%)) 93 (48) 74 (48) 0.943
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, γ glutamyl transpeptidase; HbA1c, glycated
haemoglobin.
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Table 3 Comparison according to antidiabetic therapy
On metformin On sulfonylureas On insulin
No (n=90) Yes (n=256) p Value No (n=233) Yes (n=113) p Value No (n=262) Yes (n=84) p Value
Demographic data
Age (years) 50 (42–57) 54 (46–60) 0.010 51 (43–58) 56 (49–61) <0.001 53 (46–60) 53 (46–59) 0.985
Male sex (n (%)) 35 (39) 103 (40) 0.823 90 (39) 48 (43) 0.493 102 (39) 36 (43) 0.523
Bariatric cohort (n (%)) 53 (59) 155 (61) 0.782 149 (64) 59 (52) 0.037 155 (59) 53 (63) 0.522
Metabolic data
BMI (kg/m2) 42 (29–52) 41 (33–49) 0.879 42 (33–51) 40 (31–48) 0.063 42 (32–50) 42 (33–49) 0.890
High blood pressure (n (%)) 56 (63) 205 (80) 0.001 167 (72) 94 (83) 0.023 190 (73) 71 (85) 0.029
On statins (n (%)) 23 (26) 131 (51) <0.001 89 (38) 65 (58) 0.001 103 (39) 51 (61) 0.001
Number of Antidiabetic drugs 0 (0–1) 2 (1–2) <0.001 1 (1–2) 2 (2–3) <0.001 1 (1–2) 2 (2–3) <0.001
Metformin (n (%)) − − − 156 (67) 100 (89) <0.001 190 (73) 66 (79) 0.271
Sulfonylureas (n (%)) 13 (14) 100 (39) <0.001 − − − 91 (35) 22 (26) 0.146
Insulin (n (%)) 18 (20) 66 (26) 0.271 62 (27) 22 (20) 0.146 − − −
Metabolic syndrome (n (%)) 71 (84) 241 (97) <0.001 206 (92) 106 (97) 0.049 232 (92) 80 (99) 0.026
Biochemical data
HbA1c (%) 6.9 (6.5–7.6) 7.2 (6.6–8.3) 0.014 7.0 (6.4–7.9) 7.5 (6.8–8.4) <0.001 6.9 (6.3–7.5) 8.2 (7.5–9.0) <0.001
Triglyceridaemia (mmol/L) 1.8 (1.2–2.8) 1.7 (1.2–2.3) 0.379 1.7 (1.2–2.5) 1.7 (1.1–2.3) 0.435 1.7 (1.2–2.3) 1.8 (1.2–2.8) 0.064
Total cholesterol (mmol/L) 5.1 (4.3–5.9) 4.5 (4.0–5.2) <0.001 4.7 (4.0–5.5) 4.6 (4.1–5.4) 0.767 4.7 (4.1–5.5) 4.6 (3.8–5.2) 0.170
HDL cholesterol (mmol/L) 1.1 (1.0–1.4) 1.1 (0.9–1.3) 0.265 1.1 (0.9–1.3) 1.2 (1.0–1.4) 0.014 1.1 (0.9–1.4) 1.1 (0.9–1.3) 0.179
AST (U/L) 31 (25–46) 31 (23–46) 0.388 32 (24–46) 28 (24–43) 0.198 31 (23–46) 30 (25–45) 0.842
ALT (U/L) 41 (28–62) 40 (26–62) 0.561 41 (28–64) 40 (26–61) 0.585 40 (26–64) 42 (27–57) 0.570
GGT (U/L) 49 (35–75) 52 (31–93) 0.940 49 (30–90) 55 (36–90) 0.156 49 (31–82) 65 (34–116) 0.016
Histological data
NASH (n (%)) 42 (47) 154 (60) 0.026 132 (57) 64 (57) 0.998 139 (53) 57 (68) 0.017
Significant fibrosis (F≥2) (n (%)) 37 (41) 130 (51) 0.114 103 (44) 64 (57) 0.030 120 (46) 47 (56) 0.105
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, γ glutamyl transpeptidase; HbA1c, glycated haemoglobin.
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use showed a positive independent association with sig-
nificant fibrosis in all the models, with the exception of
model 2 (adjusted OR (95% CI) for model 1 1.73 (0.98
to 3.05), p=0.061; model 2 1.34 (0.69 to 2.62), p=0.392;
model 3 2.04 (1.11 to 3.74), p=0.022) (table 4, figure 2A).
Associations between intensity of statin therapy and liver
damage
When assessing the independent associations between
the intensity of statin therapy and liver damage,
moderate-to-high intensity treatment remained the
only significant factor for NASH and significant fibro-
sis. Indeed, adjusted ORs of low-to-moderate intensity
statin therapy for NASH and significant fibrosis were
0.64 (0.25 to 1.64), p=0.354 and 0.92 (0.36 to 2.33),
p=0.852, respectively; in contrast, adjusted ORs of
moderate-to-high intensity regimens for NASH and
significant fibrosis were 0.54 (0.29 to 0.99), p=0.047
and 0.40 (0.21 to 0.76), p=0.005, respectively (figure
1B, 2B).
Table 4 Independent predictors of NASH and significant fibrosis
NASH Significant fibrosis
OR (95% CI) p Value OR (95% CI) p Value
Model 1 (cohort origin, age, sex, BMI, high blood pressure, triglycerides, total cholesterol and HDL cholesterol levels, HbA1c,
ALT, AST and GGT+a single drug among statins, metformin, sulfonylureas or insulin)
Statin use 0.61 (0.35 to 1.07) 0.086 0.52 (0.29 to 0.93) 0.026
Metformin use 1.24 (0.68 to 2.27) 0.476 1.06 (0.58 to 1.96) 0.841
Sulfonylureas use 0.78 (0.44 to 1.36) 0.377 1.73 (0.98 to 3.05) 0.061
Insulin use 2.15 (1.08 to 4.28) 0.029 1.26 (0.65 to 2.42) 0.493
Model 2 (cohort origin, age, sex, BMI, high blood pressure, triglycerides, total cholesterol and HDL cholesterol levels, HbA1c,
ALT, AST and GGT+number of antidiabetic drugs and a single drug among statins, metformin, sulfonylureas or insulin)
Statin use 0.57 (0.32 to 1.01) 0.055 0.46 (0.26 to 0.83) 0.010
Metformin use 1.00 (0.47 to 2.12) 0.997 0.58 (0.27 to 1.26) 0.170
Sulfonylureas use 0.55 (0.28 to 1.07) 0.076 1.34 (0.69 to 2.62) 0.392
Insulin use 2.03 (0.98 to 4.17) 0.055 1.01 (0.51 to 2.01) 0.978
Model 3 (cohort origin, age, sex, BMI, high blood pressure, triglycerides, total cholesterol and HDL cholesterol levels, HbA1c,
ALT, AST and GGT+statins, metformin, sulfonylureas and insulin at the same time)
Statin use 0.57 (0.32 to 1.01) 0.055 0.47 (0.26 to 0.84) 0.011
Metformin use 1.38 (0.74 to 2.56) 0.315 1.00 (0.53 to 1.89) 0.992
Sulfonylureas use 0.87 (0.48 to 1.56) 0.632 2.04 (1.11 to 3.74) 0.022
Insulin use 2.24 (1.11 to 4.54) 0.025 1.58 (0.79 to 3.14) 0.196
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, γ glutamyl transpeptidase; HbA1c, glycated
haemoglobin.
Figure 1 Adjusted ORs of statin and antidiabetic therapies for NASH. Association between the use of statins and antidiabetic
agents and the risk of NASH (adjusted ORs and 95% CI). (A) Whole study population. (B) Study population with statin therapy
graded as low-to-moderate (simvastatin, pravastatin, fluvastatin or lovastatin) or moderate-to-high (atorvastatin, rosuvastatin or
any statin in combination with ezetimibe) intensity. (C) In non-cirrhotic patients only (exclusion of 18 individuals with histological
cirrhosis). D) In 158 individuals with normal aminotransferases (ALT<40 U/L and AST<40 U/L). ALT, alanine aminotransferase;
AST, aspartate aminotransferase.
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Sensitivity analyses
After excluding the 18 individuals with histological liver
cirrhosis, the associations between statin use and liver
damage did not show substantial modifications; in par-
ticular, adjusted ORs of NASH and significant fibrosis
for statin use were 0.58 (0.32 to 1.04), p=0.067 and 0.47
(0.26 to 0.86), p=0.014, respectively. Similarly, insulin use
remained associated with NASH (adjusted OR (95% CI)
2.04 (1.00 to 4.19), p=0.051) and sulfonylureas use with
significant fibrosis (adjusted OR (95% CI) 2.13 (1.15 to
3.93), p=0.016) (figure 1C, 2C).
When analysing the 158 individuals with normal ami-
notransferases, the association between statin use and
NASH was lost (adjusted OR (95% CI) 0.65 (0.27 to
1.57), p=0.340). However, statin use remained signifi-
cantly and negatively associated with significant fibrosis
(adjusted OR (95% CI) 0.28 (0.11 to 0.72), p=0.008).
Interestingly, no antidiabetic agents were significantly
associated with NASH in patients with normal amino-
transferases. However, in this particular population, sul-
fonylureas and insulin were significantly and positively
associated with significant fibrosis (adjusted OR (95%
CI) of sulfonylureas: 3.23 (1.28 to 8.12), p=0.013;
adjusted OR (95% CI) of insulin: 3.68 (1.21 to 11.18),
p=0.022) (figure 1D, 2D).
DISCUSSION
The main finding of this study is that common medica-
tions used for cardiovascular prevention or glycaemic
control in diabetics are differently associated with
NAFLD histological severity. Statins demonstrated a
significant and independent negative association with
NASH and significant fibrosis. This was confirmed even
after excluding patients in whom the clinical suspicion
of advanced liver disease may have biased the decision
to treat with statins. Moreover, this beneficial association
may be largely due to moderate-to-high intensity statin
regimens, including atorvastatin, rosuvastatin and
ezetimibe-containing combinations. In contrast, insulin
and sulfonylureas were independently and positively
associated with the presence of NASH and of significant
fibrosis, respectively.
In addition to their lipid-lowering activity, statins also
have systemic anti-inflammatory, antioxidant and antith-
rombotic properties.6 This could confer a certain level
of protection against steatohepatitis and fibrosis. In this
series, the negative association between statin use and
histology was independent of demographic, anthropo-
metric and metabolic factors and concurrent antidia-
betic treatments. Statins with the highest efficacy for the
reduction of cholesterol levels were also those associated
with a reduced risk of histological lesions. This finding
corroborates the possible link between the intensity of
statin effects and hepatic protection. The few available
trials of statins in NAFLD have shown improvement of
steatosis and biomarkers of liver injury, but not on histo-
logical necroinflammation or fibrosis.10 14 24–26 These
underpowered trials contrast with several cross-sectional
studies, confirming our current findings that statin-
treated patients are less likely to have the full spectrum
of liver damage related to NAFLD.6 11 19 A multicentre
European study showed that statins were independently
associated with protection from steatosis, NASH and
Figure 2 Adjusted ORs of statin and antidiabetic therapies for Significant Fibrosis. Association between the use of statins and
antidiabetic agents and the risk of significant fibrosis (adjusted ORs and 95% CI). (A) Whole study population. (B) Study
population with statin therapy graded as low-to-moderate (simvastatin, pravastatin, fluvastatin or lovastatin) or moderate-to-high
(atorvastatin, rosuvastatin or any statin in combination with ezetimibe) intensity. (C) In non-cirrhotic patients only (exclusion of 18
individuals with histological cirrhosis). (D) In 158 individuals with normal aminotransferases (ALT<40 U/L and AST<40 U/L). ALT,
alanine aminotransferase; AST, aspartate aminotransferase.
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significant fibrosis in 1201 individuals at high risk for
NASH. In line with our findings, the authors found a
dose–dependent relationship between the intensity of
statin treatment and the reduced risk of liver damage.11
A cross-sectional study of US NAFLD patients with
T2DM confirmed that statin therapy is negatively asso-
ciated with advanced fibrosis.19 Further support for a
beneficial effect of statins comes from longitudinal
studies showing an independent reduction in overall
and liver-related morbidity and mortality in NAFLD
patients.27 Nonetheless, these data need to be inter-
preted with caution. Associations from transversal
studies do not necessarily support a causative process. In
addition and short of randomised interventions, they do
not provide specific evidence that exposure to statins
will result in histological improvement. However, the
data available so far collectively favour a wider use of
statins in NAFLD, given their cardiovascular benefits
and the demonstration that their use is not associated
with more advanced liver injury. Statins are underpre-
scribed28 despite their good safety profile in patients
with chronic liver diseases,7–9 and current recommenda-
tions for use in all patients with T2DM older than 40.29
In our high-risk cohort of diabetic, mainly obese,
NAFLD individuals, less than half of the patients were
on statins.
Antidiabetic therapies include drugs that improve
insulin sensitivity such as metformin, drugs that increase
circulating insulin levels such as sulfonylureas, or
exogenous insulin in advanced patients with relative
insulinopaenia. Our study suggests that antidiabetic
medications that increase insulin levels or deliver
exogenous insulin are independently associated with an
increased risk of progressive NAFLD. Patients treated
with sulfonylureas had a twofold increase in the risk of
significant fibrosis, while those treated with insulin had a
twofold increase in the risk of NASH. Moreover, in the
subset of individuals with normal aminotrasferases, sulfo-
nylureas and insulin were significantly associated with
significant fibrosis. These findings could be simply due
to the fact that the severity of T2DM negatively impacts
on liver histology. In fact, patients treated with sulfony-
lureas and/or insulin often have a longer duration of
T2DM or a poorer glycaemic control. However, we per-
formed several multivariate analyses adjusting for covari-
ates that are associated with steatohepatitis or significant
fibrosis in NAFLD, and all confirmed an independent
association of these drugs with liver injury. Of note,
other studies suggested that sulfonylureas and insulin
are associated with an increased risk of HCC.16 18
Insulin and the insulin-like growth factor (IGF) axis play
a pivotal role in hepatocarcinogenesis by stimulating pro-
liferation of liver cells, inhibiting apoptosis and promot-
ing cell migration.30 The effect of insulin signalling on
pathways of liver injury, inflammation and fibrogenesis is
less well established. However, it has been suggested that
hyperinsulinaemia and disruption of the IGF axis,
further to their direct hepatocarcinogenic potential,
may also be associated with progression of chronic liver
disease, including NAFLD.31 32 Consistent with our find-
ings, a recent study showed that use of insulin and sulfo-
nylureas were both positively and independently
associated with advanced fibrosis in diabetic patients
with NAFLD.19
In contrast with insulin and sulfonylureas, metformin
was not associated with advanced fibrosis in one report.19
Our study also shows that metformin is not associated
with steatohepatitis or significant fibrosis. Therapeutic
trials assessing the impact of metformin on NAFLD hist-
ology did not show beneficial effects.12 13 More recently,
however, a few preclinical and retrospective human
studies have suggested that metformin, by inhibiting hep-
atocyte proliferation, is associated with a significantly
decreased risk of HCC in patients with diabetes.15–18
While our data favour a safe use of metformin in NAFLD
diabetics, they also alert to the possibility of more
advanced liver damage associated with the use of sulfony-
lureas or exogenous insulin. Our study has several limita-
tions. Data on duration of diabetes, and dose and
duration for these drugs were not available, so it is not
possible to draw conclusions about the minimal drug
exposure required to detect an effect on liver histology.
Importantly, owing to its cross-sectional design, we have
to emphasise that only statistical associations are
described and that causative relationships between drug
intake and effects on liver histology cannot be estab-
lished on the basis of this study. Despite these limitations,
a strength of this study is the large number of patients
with thorough clinical and histological characterisation,
allowing adjustment for multiple confounders.
In conclusion, our data support the hypothesis that
statin and antidiabetic therapies commonly prescribed
in patients with diabetes are differently associated with
necroinflammation and fibrosis in NAFLD. Diabetic
patients with NAFLD who are treated with statins, expe-
cially with moderate-to-high intensity regimens, have a
lower risk of being diagnosed with advanced forms of
NAFLD. Conversely, sulfonylureas and exogenous
insulin are associated with an increased risk of NASH
and significant fibrosis. No associations were found for
metformin. These findings suggest a potential protective
effect of statins which may warrant their wider use in
high-risk, diabetic, NAFLD patients. Conversely, since
sulfonylureas and insulin are indicated for glycaemic
control despite a possible worsening of liver injury, spe-
cific pharmacological therapy for NASH is acutely
needed.
Acknowledgements The authors thank members of the LIDO (Liver Injury in
Diabetes and Obesity) Study Group: André Grimaldi, Philippe Giral, Eric
Bruckert, Arnaud Basdevant, Karine Clement, Jean-Michel Oppert, Agnès
Hartemann-Heurtier, Fabrizio Andreelli, Sophie Gombert, Sophie Jacqueminet,
Arnaud Cocaul, Fabienne Fouffelle, Joseph Moussalli, Dominique Thabut,
Pascal Lebray, Philippe Podevin, Dominique Bonnefont-Rousselot, Randa
Bittar, Yves Benhamou, Carole Bernhardt, Hôpital Pitié-Salpêtrière; Christian
Boitard, Etienne Larger, Agnès Sola, Martine El-Etr, Hôpital Hotel-Dieu;
Jean-François Gautier, Hôpital Saint-Louis; Lawrence Serfaty, Chantal
Housset, Jacqueline Capeau, Hôpital Saint-Antoine, all in Paris, France.
8 Nascimbeni F, Aron-Wisnewsky J, Pais R, et al. BMJ Open Gastro 2016;3:e000075. doi:10.1136/bmjgast-2015-000075
Open Access
Contributors FN, the guarantor of the article, analysed the data and wrote the
paper; JA-W, RP, CP, FC and PB performed the research, collected the data
and revised the paper; JT, TP and KC contributed to the design of the study;
VR designed the research study and revised the paper. All authors approved
the final version of the article, including the authorship list.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Leite NC, Salles GF, Araujo AL, et al. Prevalence and associated
factors of non-alcoholic fatty liver disease in patients with type-2
diabetes mellitus. Liver Int 2009;29:113–19.
2. Williamson RM, Price JF, Glancy S, et al. Prevalence of and risk
factors for hepatic steatosis and nonalcoholic fatty liver disease in
people with type 2 diabetes: the Edinburgh type 2 diabetes study.
Diabetes Care 2011;34:1139–44.
3. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in
patients with nonalcoholic fatty liver disease. N Engl J Med
2010;363:1341–50.
4. American Diabetes Association. Standards of medical care in
diabetes—2014. Diabetes Care 2014;37(Suppl 1):S14–80.
5. Nascimbeni F, Pais R, Bellentani S, et al. From NAFLD in clinical
practice to answers from guidelines. J Hepatol 2013;59:859–71.
6. Pastori D, Polimeni L, Baratta F, et al. The efficacy and safety of
statins for the treatment of non-alcoholic fatty liver disease. Dig Liver
Dis 2015;47:4–11.
7. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated
liver enzymes are not at higher risk for statin hepatotoxicity.
Gastroenterology 2004;126:1287–92.
8. Browning JD. Statins and hepatic steatosis: perspectives from the
Dallas heart study. Hepatology 2006;44:466–71.
9. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of
high-dose pravastatin in hypercholesterolemic patients with
well-compensated chronic liver disease: results of a prospective,
randomized, double-blind, placebo-controlled, multicenter trial.
Hepatology 2007;46:1453–63.
10. Ekstedt M, Franzén LE, Mathiesen UL, et al. Statins in non-alcoholic
fatty liver disease and chronically elevated liver enzymes: a
histopathological follow-up study. J Hepatol 2007;47:135–41.
11. Dongiovanni P, Petta S, Mannisto V, et al. Statin use and
non-alcoholic steatohepatitis in at risk individuals. J Hepatol
2015;63:705–12.
12. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of
patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther
2004;19:537–44.
13. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled
trial of metformin versus vitamin E or prescriptive diet in
nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082–
90.
14. Musso G, Cassader M, Rosina F, et al. Impact of current treatments
on liver disease, glucose metabolism and cardiovascular risk in
non-alcoholic fatty liver disease (NAFLD): a systematic review and
meta-analysis of randomised trials. Diabetologia 2012;55:885–904.
15. Donadon V, Balbi M, Mas MD, et al. Metformin and reduced risk of
hepatocellular carcinoma in diabetic patients with chronic liver
disease. Liver Int 2010;30:750–8.
16. Singh S, Singh PP, Singh AG, et al. Anti-diabetic medications and
the risk of hepatocellular cancer: a systematic review and
meta-analysis. Am J Gastroenterol 2013;108:881–91; quiz 92.
17. Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases
hepatocellular carcinoma risk in a dose-dependent manner:
population-based and in vitro studies. Gut 2013;62:606–15.
18. Hassan MM, Curley SA, Li D, et al. Association of diabetes duration
and diabetes treatment with the risk of hepatocellular carcinoma.
Cancer 2010;116:1938–46.
19. Goh GBB, Pagadala MR, Dasarathy J, et al. Diabetes mellitus,
insulin, sulfonylurea and advanced fibrosis in non-alcoholic fatty liver
disease. J Diabetes Metab 2014;5:410.
20. American Diabetes Association. Diagnosis and classification of
diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62–9.
21. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic
syndrome: a joint interim statement of the International Diabetes
Federation Task Force on Epidemiology and prevention; National
Heart, Lung, and Blood Institute; American Heart Association; World
Heart Federation; International Atherosclerosis Society; and
International Association for the study of obesity. Circulation
2009;120:1640–5.
22. Bedossa P, Consortium FP. Utility and appropriateness of the fatty
liver inhibition of progression (FLIP) algorithm and steatosis, activity,
and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic
fatty liver disease. Hepatology 2014;60:565–75.
23. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a
histological scoring system for nonalcoholic fatty liver disease.
Hepatology 2005;41:1313–21.
24. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of
long-term statin treatment for cardiovascular events in patients with
coronary heart disease and abnormal liver tests in the Greek
Atorvastatin and Coronary Heart Disease Evaluation (GREACE)
Study: a post-hoc analysis. Lancet 2010;376:1916–22.
25. Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for
the treatment of nonalcoholic fatty liver disease: the St Francis Heart
Study randomized clinical trial. Am J Gastroenterol 2011;106:71–7.
26. Nelson A, Torres DM, Morgan AE, et al. A pilot study using
simvastatin in the treatment of nonalcoholic steatohepatitis: a
randomized placebo-controlled trial. J Clin Gastroenterol
2009;43:990–4.
27. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no
other histologic features, Is associates with long-term outcomes of
patients with nonalcoholic fatty liver disease. Gastroenterology
2015;149:389–97.e10.
28. Blais P, Lin M, Kramer JR, et al. Statins are underutilized in patients
with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci
2015.
29. American Diabetes Association. (8) Cardiovascular disease and risk
management. Diabetes Care 2015;38(Suppl):S49–57.
30. Enguita-Germán M, Fortes P. Targeting the insulin-like growth factor
pathway in hepatocellular carcinoma. World J Hepatol 2014;6:716–
37.
31. Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like
growth factor-1 stimulate proliferation and type I collagen
accumulation by human hepatic stellate cells: differential effects on
signal transduction pathways. Hepatology 1999;29:1743–51.
32. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and
hyperinsulinemia stimulate connective tissue growth factor
expression: a potential mechanism involved in progression to fibrosis
in nonalcoholic steatohepatitis. Hepatology 2001;34Pt 1):738–44.
Nascimbeni F, Aron-Wisnewsky J, Pais R, et al. BMJ Open Gastro 2016;3:e000075. doi:10.1136/bmjgast-2015-000075 9
Open Access
